Collecting duct carcinoma of the kidney: Disease characteristics and treatment outcomes from the National Cancer Database

An Analysis of Staging and Treatment Trends for Upper Tract Urothelial Carcinoma in the National Cancer Database

Clin Genitourin Cancer.

Browne BM, Stensland KD, Moynihan MJ, Canes D

doi: 10.1016/j.clgc.2018.01.015.

Erectile and Sexual Functions and DysfunctionsUrinary IncontinenceUro-Oncology

Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade

Cancer Med.

Jang JW, Drumm MR, Efstathiou JA, Paly JJ, Niemierko A, Ancukiewicz M, Talcott JA, Clark JA, Zietman AL

doi: 10.1002/cam4.1103.

Uro-Oncology

Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic

Eur Urol.

Wallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N, Gillessen S, Bossi A, Roupret M, Powles T, Necchi A, Catto JWF, Klaassen Z

doi: 10.1016/j.eururo.2020.04.063.

Overactive BladderUro-OncologyPregnancy and Childbirth

Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population

Clin Genitourin Cancer.

Robinson AG, Wei X, Vera-Badillo FE, Mackillop WJ, Booth CM

doi: 10.1016/j.clgc.2016.12.025.

Uro-Oncology

Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received

Eur Urol.

Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Young GJ, Dutton SJ, Walsh EI, Martin RM, Peters TJ, Turner EL, Mason M, Bollina P, Catto J, Doherty A, Gillatt D, Gnanapragasam V, Holding P, Hughes O, Kockelbergh R, Kynaston H, Oxley J, Paul A, Paez E, Rosario DJ, Rowe E, Staffurth J, Altman DG, Hamdy FC, ProtecT Study Group.

doi: 10.1016/j.eururo.2019.10.030.

Erectile and Sexual Functions and Dysfunctions

Characteristics of Men With Peyronie's Disease and Collagenase Clostridium Histolyticum Treatment Failure: Predictors of Surgical Intervention and Outcomes

J Sex Med.

Bajic P, Wiggins AB, Ziegelmann MJ, Levine LA

doi: 10.1016/j.jsxm.2020.02.002.

Overactive BladderUro-Oncology

Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer

Int J Urol.

Kobatake K, Hayashi T, Black PC, Goto K, Sentani K, Kaneko M, Yasui W, Mita K, Teishima J, Matsubara A

doi: 10.1111/iju.13389.

Uro-Oncology

Systematic Review of Time to Definitive Treatment for Intermediate-Risk and High-Risk Prostate Cancer: Are Delays Associated with Worse Outcomes?

J Urol

Nguyen DD, Haeuser L, Paciotti M, Reitblat C, Cellini J, Lipsitz SR, Kibel AS, Choudhury AD, Cone EB, Trinh QD

doi: 10.1097/JU.0000000000001601

Uro-Oncology

Outcome of kidney function after ischaemic and zero-ischaemic laparoscopic and open nephron-sparing surgery for renal cell cancer

BMC Nephrol.

Ebbing J, Menzel F, Frumento P, Miller K, Ralla B, Fuller TF, Busch J, Collins JW, Adding C, Seifert HH, Ardelt P, Wetterauer C, Westhoff T, Kempkensteffen C

doi: 10.1186/s12882-019-1215-3.

Related content

An Analysis of Staging and Treatment Trends for Upper Tract Urothelial Carcinoma in the National Cancer Database

Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade

Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic

Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population

Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received

Characteristics of Men With Peyronie's Disease and Collagenase Clostridium Histolyticum Treatment Failure: Predictors of Surgical Intervention and Outcomes

Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer

Systematic Review of Time to Definitive Treatment for Intermediate-Risk and High-Risk Prostate Cancer: Are Delays Associated with Worse Outcomes?

Outcome of kidney function after ischaemic and zero-ischaemic laparoscopic and open nephron-sparing surgery for renal cell cancer